Loading clinical trials...
Loading clinical trials...
Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction
Conditions
Interventions
erlotinib hydrochloride
laboratory biomarker analysis
Locations
1
United States
Cancer and Leukemia Group B
Chicago, Illinois, United States
Start Date
December 1, 2001
Primary Completion Date
July 1, 2007
Last Updated
January 16, 2013
NCT02015819
NCT01478321
NCT01234805
NCT00045110
NCT00823797
NCT02194452
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions